GT Biopharma (GTBP) Year-over-year earnings per share growth for the last twelve months

Corporate company logo of GT Biopharma Inc (GTBP)

The efficiency of GT Biopharma, Inc. (GTBP) relies on strict adherence to temperature controls during the transportation of oncology drugs. The quarterly EPS growth rate reflects the asset's current dynamics, where the parameter value equals 98.10. Geopolitical risks and challenges regarding international patent protection complicate development. The absence of current sales due to the testing phase deprives the company of market pricing power, leaving its capitalization dependent on future discoveries.

gtbiopharma.com (GTBP) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/16/2026

GT Biopharma - analytical breakdowns and key metrics (GTBP)

- market value and analyst target forecast:
Summary company analytics:GT Biopharma Corp - GTBP
Finished products of gtbiopharma.com

For the investor, the stability of GT Biopharma, Inc. (GTBP) is confirmed by streamlined bioprotein logistics through a network of global laboratories, which minimizes operational disruptions. When analyzing the quarterly EPS growth efficiency metric on the GURU.Markets platform, the trend of net income per share relative to the previous period should be evaluated as an indicator of the business's ability to scale profitability amid central bank liquidity volatility.

Direct competitors

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics, Inc.)|Vor Bio Inc. (VOR) - Earnings per share growth in annualized terms for the last twelve months|NKTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coeptistx.com|ATNM (Actinium Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|ESLA: Year-over-year earnings per share growth rate for the last twelve months|CASI (CASI Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Marker Therapeutics|INAB (IN8bio, Inc.) - Year-over-year net earnings per share change for the last twelve months|Eterna Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months